This project aims to bring cutting-edge molecular diagnostics to Saudi Arabia using a 23-gene panel to detect key genetic ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.

A bladder ultrasound gives providers clues about how the bladder expands and holds urine. This article lists conditions ...

Lower abdominal visceral fat area (VFA), older age, and prolonged surgery are independent risk factors for developing ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a new ...

Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months. On Nov. 6, 2024, ...

The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a ...

A recent study reveals that extended lymphadenectomy offers no survival advantage over standard lymphadenectomy for patients ...

This partnership unites the expertise of KFSHRC’s Urology Department with BCRC’s research capabilities to advance ...